AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. SLN
  4. [Form 4] Silence Therapeutics Plc American Depository Share Insider Trading Activity

[Form 4] Silence Therapeutics Plc American Depository Share Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Silence Therapeutics plc (SLN) 鈥� Form 4 insider activity: Director and 10% owner Richard Ian Griffiths, through Cream Capital Ltd., reported two open-market purchases of American Depositary Shares (ADS).

  • 31 Jul 2025: 14,342 ADS at $6.18
  • 1 Aug 2025: 4,034 ADS at $6.14

The combined 18,376 ADS cost roughly $113 k and lifted his indirect holding to 11,825,861 ADS. Each ADS converts into three ordinary shares and has no expiration date. Griffiths disclaims beneficial ownership beyond his pecuniary interest.

The transactions modestly increase an already large position (<0.02 % incremental) and do not affect control status, but fresh insider buying can be viewed as a mild vote of confidence. No sales, options, or other derivative moves were disclosed.

Silence Therapeutics plc (SLN) 鈥� Attivit脿 insider nel modulo 4: Il direttore e proprietario del 10% Richard Ian Griffiths, tramite Cream Capital Ltd., ha segnalato due acquisti sul mercato aperto di American Depositary Shares (ADS).

  • 31 lug 2025: 14.342 ADS a 6,18 $
  • 1 ago 2025: 4.034 ADS a 6,14 $

Le 18.376 ADS complessive sono costate circa 113.000 $ e hanno portato la sua partecipazione indiretta a 11.825.861 ADS. Ogni ADS si converte in tre azioni ordinarie e non ha data di scadenza. Griffiths nega la propriet脿 beneficiaria oltre il suo interesse patrimoniale.

Le transazioni aumentano modestamente una posizione gi脿 significativa (<0,02% in pi霉) e non modificano lo status di controllo, ma i nuovi acquisti da parte dell鈥檌nsider possono essere interpretati come un leggero segnale di fiducia. Non sono state dichiarate vendite, opzioni o altre operazioni su derivati.

Silence Therapeutics plc (SLN) 鈥� Actividad insider en el Formulario 4: El director y propietario del 10% Richard Ian Griffiths, a trav茅s de Cream Capital Ltd., report贸 dos compras en el mercado abierto de American Depositary Shares (ADS).

  • 31 jul 2025: 14,342 ADS a 6,18 $
  • 1 ago 2025: 4,034 ADS a 6,14 $

Las 18,376 ADS combinadas costaron aproximadamente 113,000 $ y elevaron su participaci贸n indirecta a 11,825,861 ADS. Cada ADS se convierte en tres acciones ordinarias y no tiene fecha de vencimiento. Griffiths niega la propiedad beneficiaria m谩s all谩 de su inter茅s econ贸mico.

Las transacciones incrementan modestamente una posici贸n ya grande (<0,02% adicional) y no afectan el estatus de control, pero las nuevas compras de insiders pueden verse como un leve voto de confianza. No se divulgaron ventas, opciones u otros movimientos derivados.

Silence Therapeutics plc (SLN) 鈥� Form 4 雮措秬鞛� 頇滊彊: 鞚挫偓鞚挫瀽 10% 靻岇湢欤检澑 Richard Ian Griffiths臧� Cream Capital Ltd.毳� 韱淀暣 氙戈淡鞓堩儊歃濎劀(ADS)毳� 霊� 彀 瓿店皽鞁滌灔 毵れ垬頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟.

  • 2025雲� 7鞗� 31鞚�: 14,342 ADS毳� $6.18鞐� 毵れ垬
  • 2025雲� 8鞗� 1鞚�: 4,034 ADS毳� $6.14鞐� 毵れ垬

齑� 18,376 ADS毳� 鞎� $113,000鞐� 毵れ瀰頃橃棳 攴胳潣 臧勳爲 氤挫湢霟夓澊 11,825,861 ADS搿� 電橃柎雮姷雼堧嫟. 臧� ADS電� 氤错喌欤� 3欤茧 鞝勴櫂 臧�電ロ晿氅� 毵岅赴鞚检澊 鞐嗢姷雼堧嫟. Griffiths電� 鞛愳嫚鞚� 旮堨爠鞝� 鞚挫澋鞚� 雱橃柎靹� 鞁れ 靻岇湢甓岇潉 攵�鞚疙暕雼堧嫟.

鞚措矆 瓯半灅電� 鞚措 韥� 歆�攵勳潉 靻岉彮 歃濌皜鞁滍偍 瓴冹溂搿� (<0.02% 歃濌皜) 歆�氚瓣秾鞐愲姅 鞓來枼鞚� 氙胳箻歆� 鞎婌溂雮�, 雮措秬鞛愳潣 鞁犼窚 毵れ垬電� 鞎疥皠鞚� 鞁犽 鞁犿樃搿� 氤� 靾� 鞛堨姷雼堧嫟. 毵る弰, 鞓奠厴 霕愲姅 旮绊儉 韺岇儩靸來拡 瓯半灅電� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.

Silence Therapeutics plc (SLN) 鈥� Activit茅 des initi茅s selon le formulaire 4 : Le directeur et d茅tenteur de 10 % Richard Ian Griffiths, via Cream Capital Ltd., a d茅clar茅 deux achats sur le march茅 libre d鈥橝merican Depositary Shares (ADS).

  • 31 juil. 2025 : 14 342 ADS 脿 6,18 $
  • 1 ao没t 2025 : 4 034 ADS 脿 6,14 $

Les 18 376 ADS combin茅es ont co没t茅 environ 113 000 $ et ont port茅 sa participation indirecte 脿 11 825 861 ADS. Chaque ADS se convertit en trois actions ordinaires et n鈥檃 pas de date d鈥檈xpiration. Griffiths d茅cline toute propri茅t茅 b茅n茅ficiaire au-del脿 de son int茅r锚t p茅cuniaire.

Ces transactions augmentent modestement une position d茅j脿 importante (<0,02 % d鈥檌ncr茅ment) et n鈥檃ffectent pas le statut de contr么le, mais ces nouveaux achats d鈥檌niti茅s peuvent 锚tre vus comme un l茅ger signe de confiance. Aucune vente, option ou autre op茅ration d茅riv茅e n鈥檃 茅t茅 divulgu茅e.

Silence Therapeutics plc (SLN) 鈥� Insider-Aktivit盲ten gem盲脽 Formular 4: Direktor und 10%-Eigent眉mer Richard Ian Griffiths meldete 眉ber Cream Capital Ltd. zwei K盲ufe von American Depositary Shares (ADS) am offenen Markt.

  • 31. Juli 2025: 14.342 ADS zu 6,18 $
  • 1. Aug. 2025: 4.034 ADS zu 6,14 $

Die insgesamt 18.376 ADS kosteten rund 113.000 $ und erh枚hten seinen indirekten Bestand auf 11.825.861 ADS. Jede ADS wandelt sich in drei Stammaktien um und hat kein Verfallsdatum. Griffiths bestreitet wirtschaftliches Eigentum 眉ber sein finanzielles Interesse hinaus.

Die Transaktionen erh枚hen eine bereits gro脽e Position nur geringf眉gig (<0,02 % Zuwachs) und beeinflussen den Kontrollstatus nicht, doch frische Insiderk盲ufe k枚nnen als leichtes Vertrauenssignal gewertet werden. Verk盲ufe, Optionen oder andere Derivatgesch盲fte wurden nicht offengelegt.

Positive
  • Insider accumulation: 10% owner purchased 18,376 ADS, signalling incremental confidence.
Negative
  • Immaterial size: Purchases represent less than 0.02 % of existing stake, limiting market impact.

Insights

TL;DR: Small incremental buy by major holder; sentiment slightly positive but financially immaterial.

The purchase totalling 18,376 ADS (~$113 k) is negligible versus Griffiths鈥� 11.8 million-unit stake and therefore does not change the ownership landscape or imply a material capital commitment. However, continued accumulation by a 10 % owner鈥攅xecuted in the open market rather than via option exercise鈥攐ften serves as a behavioral signal of confidence in future prospects. The absence of any dispositions or hedging activity keeps the reading neutral-to-positive. From a liquidity standpoint, the trade size is unlikely to influence share supply-demand dynamics. Overall impact on valuation or governance risk is minimal.

Silence Therapeutics plc (SLN) 鈥� Attivit脿 insider nel modulo 4: Il direttore e proprietario del 10% Richard Ian Griffiths, tramite Cream Capital Ltd., ha segnalato due acquisti sul mercato aperto di American Depositary Shares (ADS).

  • 31 lug 2025: 14.342 ADS a 6,18 $
  • 1 ago 2025: 4.034 ADS a 6,14 $

Le 18.376 ADS complessive sono costate circa 113.000 $ e hanno portato la sua partecipazione indiretta a 11.825.861 ADS. Ogni ADS si converte in tre azioni ordinarie e non ha data di scadenza. Griffiths nega la propriet脿 beneficiaria oltre il suo interesse patrimoniale.

Le transazioni aumentano modestamente una posizione gi脿 significativa (<0,02% in pi霉) e non modificano lo status di controllo, ma i nuovi acquisti da parte dell鈥檌nsider possono essere interpretati come un leggero segnale di fiducia. Non sono state dichiarate vendite, opzioni o altre operazioni su derivati.

Silence Therapeutics plc (SLN) 鈥� Actividad insider en el Formulario 4: El director y propietario del 10% Richard Ian Griffiths, a trav茅s de Cream Capital Ltd., report贸 dos compras en el mercado abierto de American Depositary Shares (ADS).

  • 31 jul 2025: 14,342 ADS a 6,18 $
  • 1 ago 2025: 4,034 ADS a 6,14 $

Las 18,376 ADS combinadas costaron aproximadamente 113,000 $ y elevaron su participaci贸n indirecta a 11,825,861 ADS. Cada ADS se convierte en tres acciones ordinarias y no tiene fecha de vencimiento. Griffiths niega la propiedad beneficiaria m谩s all谩 de su inter茅s econ贸mico.

Las transacciones incrementan modestamente una posici贸n ya grande (<0,02% adicional) y no afectan el estatus de control, pero las nuevas compras de insiders pueden verse como un leve voto de confianza. No se divulgaron ventas, opciones u otros movimientos derivados.

Silence Therapeutics plc (SLN) 鈥� Form 4 雮措秬鞛� 頇滊彊: 鞚挫偓鞚挫瀽 10% 靻岇湢欤检澑 Richard Ian Griffiths臧� Cream Capital Ltd.毳� 韱淀暣 氙戈淡鞓堩儊歃濎劀(ADS)毳� 霊� 彀 瓿店皽鞁滌灔 毵れ垬頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟.

  • 2025雲� 7鞗� 31鞚�: 14,342 ADS毳� $6.18鞐� 毵れ垬
  • 2025雲� 8鞗� 1鞚�: 4,034 ADS毳� $6.14鞐� 毵れ垬

齑� 18,376 ADS毳� 鞎� $113,000鞐� 毵れ瀰頃橃棳 攴胳潣 臧勳爲 氤挫湢霟夓澊 11,825,861 ADS搿� 電橃柎雮姷雼堧嫟. 臧� ADS電� 氤错喌欤� 3欤茧 鞝勴櫂 臧�電ロ晿氅� 毵岅赴鞚检澊 鞐嗢姷雼堧嫟. Griffiths電� 鞛愳嫚鞚� 旮堨爠鞝� 鞚挫澋鞚� 雱橃柎靹� 鞁れ 靻岇湢甓岇潉 攵�鞚疙暕雼堧嫟.

鞚措矆 瓯半灅電� 鞚措 韥� 歆�攵勳潉 靻岉彮 歃濌皜鞁滍偍 瓴冹溂搿� (<0.02% 歃濌皜) 歆�氚瓣秾鞐愲姅 鞓來枼鞚� 氙胳箻歆� 鞎婌溂雮�, 雮措秬鞛愳潣 鞁犼窚 毵れ垬電� 鞎疥皠鞚� 鞁犽 鞁犿樃搿� 氤� 靾� 鞛堨姷雼堧嫟. 毵る弰, 鞓奠厴 霕愲姅 旮绊儉 韺岇儩靸來拡 瓯半灅電� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.

Silence Therapeutics plc (SLN) 鈥� Activit茅 des initi茅s selon le formulaire 4 : Le directeur et d茅tenteur de 10 % Richard Ian Griffiths, via Cream Capital Ltd., a d茅clar茅 deux achats sur le march茅 libre d鈥橝merican Depositary Shares (ADS).

  • 31 juil. 2025 : 14 342 ADS 脿 6,18 $
  • 1 ao没t 2025 : 4 034 ADS 脿 6,14 $

Les 18 376 ADS combin茅es ont co没t茅 environ 113 000 $ et ont port茅 sa participation indirecte 脿 11 825 861 ADS. Chaque ADS se convertit en trois actions ordinaires et n鈥檃 pas de date d鈥檈xpiration. Griffiths d茅cline toute propri茅t茅 b茅n茅ficiaire au-del脿 de son int茅r锚t p茅cuniaire.

Ces transactions augmentent modestement une position d茅j脿 importante (<0,02 % d鈥檌ncr茅ment) et n鈥檃ffectent pas le statut de contr么le, mais ces nouveaux achats d鈥檌niti茅s peuvent 锚tre vus comme un l茅ger signe de confiance. Aucune vente, option ou autre op茅ration d茅riv茅e n鈥檃 茅t茅 divulgu茅e.

Silence Therapeutics plc (SLN) 鈥� Insider-Aktivit盲ten gem盲脽 Formular 4: Direktor und 10%-Eigent眉mer Richard Ian Griffiths meldete 眉ber Cream Capital Ltd. zwei K盲ufe von American Depositary Shares (ADS) am offenen Markt.

  • 31. Juli 2025: 14.342 ADS zu 6,18 $
  • 1. Aug. 2025: 4.034 ADS zu 6,14 $

Die insgesamt 18.376 ADS kosteten rund 113.000 $ und erh枚hten seinen indirekten Bestand auf 11.825.861 ADS. Jede ADS wandelt sich in drei Stammaktien um und hat kein Verfallsdatum. Griffiths bestreitet wirtschaftliches Eigentum 眉ber sein finanzielles Interesse hinaus.

Die Transaktionen erh枚hen eine bereits gro脽e Position nur geringf眉gig (<0,02 % Zuwachs) und beeinflussen den Kontrollstatus nicht, doch frische Insiderk盲ufe k枚nnen als leichtes Vertrauenssignal gewertet werden. Verk盲ufe, Optionen oder andere Derivatgesch盲fte wurden nicht offengelegt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Griffiths Richard Ian
(Last) (First) (Middle)
FLOOR 1 LIBERATION STATION
ESPLANADE
(Street)
ST HELIER Y9 JE2 3AS
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Silence Therapeutics plc [ SLN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/31/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
American Depositary Shares $6.18 07/31/2025 P 14,342 (1) (1) Ordinary Shares 43,026 (1) 11,821,827 I See footnote(2)
American Depositary Shares $6.14 08/01/2025 P 4,034 (1) (1) Ordinary Shares 12,102 (1) 11,825,861 I See footnote(2)
Explanation of Responses:
1. Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date.
2. The securities are held by Cream Capital Limited ("Cream"). Mr. Griffiths is a director and the controlling shareholder of Cream. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
/s/ Richard Ian Griffiths 08/04/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many Silence Therapeutics (SLN) ADS did Richard Griffiths purchase?

He bought 18,376 American Depositary Shares across two days.

At what prices were the SLN ADS purchased?

$6.18 on 31 Jul 2025 for 14,342 ADS and $6.14 on 1 Aug 2025 for 4,034 ADS.

What is Griffiths鈥� total SLN ADS ownership after these transactions?

He indirectly holds 11,825,861 ADS through Cream Capital Ltd.

How many ordinary shares do the purchased ADS represent?

Each ADS equals three ordinary shares, so the 18,376 ADS correspond to 55,128 ordinary shares.

Does the Form 4 disclose any share sales or option exercises?

No. The filing lists only open-market purchases; no dispositions or option activity are reported.
Stock SLN logo
Silence Therapeutics Plc

NASDAQ:SLN

SLN Rankings

#5224 Ranked by Market Cap
N/A Ranked by Dividends

SLN Latest News

Aug 7, 2025
Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Jun 12, 2025
Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera
May 8, 2025
Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 6, 2025
Silence Therapeutics Welcomes Tim McInerney to Board of Directors
Mar 5, 2025
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

SLN Latest SEC Filings

Aug 7, 2025
[10-Q] Silence Therapeutics Plc American Depository Share Quarterly Earnings Report
Aug 7, 2025
[8-K] Silence Therapeutics Plc American Depository Share Reports Material Event
Jul 31, 2025
[Form 4] Silence Therapeutics Plc American Depository Share Insider Trading Activity
Jul 23, 2025
[Form 4] Silence Therapeutics Plc American Depository Share Insider Trading Activity
Jul 16, 2025
[Form 4] Silence Therapeutics Plc American Depository Share Insider Trading Activity

SLN Stock Data

251.27M
34.57M
24.38%
48.85%
1.95%
Biotechnology
Pharmaceutical Preparations
United Kingdom
LONDON